Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE

Type C hepatic encephalopathy (HE) is a neuropsychiatric disease caused by chronic liver disease. Management of type C HE remains an important challenge because treatment options are limited. Both the antibiotic rifaximin and probiotics have been reported to reduce the symptoms of HE, but longitudin...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-09, Vol.11 (1), p.17988-17988, Article 17988
Main Authors: Flatt, Emmanuelle, McLin, Valérie A., Braissant, Olivier, Pierzchala, Katarzyna, Mastromarino, Paola, Mitrea, Stefanita-Octavian, Sessa, Dario, Gruetter, Rolf, Cudalbu, Cristina
Format: Article
Language:English
Subjects:
639/766/930/878
692/308/1426
692/4020/4021/1607
Bile ducts
Cerebellum
Hepatic encephalopathy
Humanities and Social Sciences
Liver diseases
Longitudinal studies
Mental disorders
Molecular modelling
multidisciplinary
Probiotics
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type C hepatic encephalopathy (HE) is a neuropsychiatric disease caused by chronic liver disease. Management of type C HE remains an important challenge because treatment options are limited. Both the antibiotic rifaximin and probiotics have been reported to reduce the symptoms of HE, but longitudinal studies assessing their effects on brain metabolism are lacking and the molecular mechanisms underpinning their effects are not fully understood. Therefore, we evaluated in detail the effects of these different treatments on the neurometabolic changes associated with type C HE using a multimodal approach including ultra-high field in vivo 1 H MRS. We analyzed longitudinally the effect of rifaximin alone or in combination with the probiotic Vivomixx on the brain metabolic profile in the hippocampus and cerebellum of bile duct ligated (BDL) rats, an established model of type C HE. Overall, while rifaximin alone appeared to induce no significant effect on the neurometabolic profile of BDL rats, its association with the probiotic resulted in more attenuated neurometabolic alterations in BDL rats followed longitudinally (i.e. a smaller increase in Gln and milder decrease in Glu and Cr levels). Given that both rifaximin and some probiotics are used in the treatment of HE, the implications of these findings may be clinically relevant.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-97018-8